Loss of IL-6 Receptor Expression in Cervical Carcinoma Cells Inhibits Autocrine IL-6 Stimulation: Abrogation of Constitutive Monocyte Chemoattractant Protein-1 Production
Open Access
- 15 August 2000
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 165 (4) , 1939-1948
- https://doi.org/10.4049/jimmunol.165.4.1939
Abstract
IL-6 is synthesized in human pampilloma virus (HPV)-transformed cervical carcinoma cell lines and is supposed to stimulate these cells in an autocrine manner. We studied IL-6 production and responsiveness in nonmalignant HPV-transformed keratinocytes and cervical carcinoma cells in detail. IL-6 was detected in cervical carcinomas in situ. Correspondingly, HPV-positive carcinoma cell lines expressed high IL-6 levels. However, these carcinoma cell lines showed low responsiveness to IL-6 as revealed by low constitutive STAT3 binding activity, which was not further enhanced by exogenous IL-6. In contrast, in vitro-transformed nonmalignant keratinocytes without endogenous IL-6 production strongly responded to exogenous IL-6 with activation of STAT3. STAT3 protein expression levels were comparable in both responsive and nonresponsive cell lines. Also, gp130, the upstream signal-transducing receptor subunit conveying IL-6 signals into the cell, was expressed in all tested cell lines. However, the IL-6 binding subunit gp80 was lost in the malignant cells. Addition of soluble gp80 was sufficient to restore IL-6 responsiveness in carcinoma cells as shown by enhanced activation of STAT3 binding activity. As a consequence of the restored IL-6 responsiveness, carcinoma cells strongly produced the chemokine monocyte chemoattractant protein-1 (MCP-1). Our data demonstrate that cervical carcinoma cells producing high amounts of IL-6 only weakly respond to IL-6 in an autocrine manner due to limited gp80 expression. While production of IL-6 might contribute to a local immunosuppressive effect, silencing an autocrine IL-6 response prevents constitutive production of the mononuclear cell-attracting chemokine MCP-1. Both mechanisms might help the tumor to escape the immune system.Keywords
This publication has 68 references indexed in Scilit:
- Major role of the soluble interleukin‐6/interleukin‐6 receptor complex for the proliferation of interleukin‐6‐dependent human myeloma cell linesEuropean Journal of Immunology, 1997
- gp130 AND THE INTERLEUKIN-6 FAMILY OF CYTOKINESAnnual Review of Immunology, 1997
- Role of IL-6 and Its Soluble Receptor in Induction of Chemokines and Leukocyte RecruitmentPublished by Elsevier ,1997
- A cytotoxic CD40/p55 tumor necrosis factor receptor hybrid detects CD40 ligand on herpesvirus saimiri‐transformed T cellsEuropean Journal of Immunology, 1995
- Stat3: a STAT Family Member Activated by Tyrosine Phosphorylation in Response to Epidermal Growth Factor and Interleukin-6Science, 1994
- Constitutive release of IL6 by human papillomavirus type 16 (HPV16)-harboring keratinocytes: A mechanism augmenting the NK-cell-mediated lysis of HPV-bearing neoplastic cellsCellular Immunology, 1991
- Molecular cloning and expression of an IL-6 signal transducer, gp130Cell, 1990
- Interleukin‐6 (IL‐6) functions as an in vitro autocrine growth factor in renal cell carcinomasFEBS Letters, 1989
- Induction of β2-interferon by tumor necrosis factor: A homeostatic mechanism in the control of cell proliferationCell, 1986
- Dye Uptake Methods for Assessing Viral Cytopathogenicity and their Application to Interferon AssaysJournal of General Virology, 1969